Allergy News – General Allergy/Imm Articles

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 email addresses.
*From Email:
*To Email:
To Email:
To Email:
To Email:
To Email:

Vaccination With Agonist Peptide PSA: 154-163 (155L) Derived From Prostate Specific Antigen Induced CD8 T-Cell Response to the Native Peptide PSA: 154-163 But Failed to Induce the Reactivity Against Tumor Targets Expressing PSA: A Phase 2 Study in Patients With Recurrent Prostate Cancer
Kouiavskaia DV et al. - There were no significant changes in serum PSA level in any subject. No serious adverse events were observed. PSA: 154-163 is not an effective immunogen when given with Montanide ISA-51. The PSA: 154-163 peptide is poorly processed from endogenous PSA and therefore represents a cryptic epitope of PSA in HLA-A2 antigen-presenting cells. [more...]

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine

Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics

Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor